Evidence map›Paper›PMID 38910578›Full record

ArticleFuture medicinal chemistry2024

Exploring the current advancements of quercetin nanoformulations alleviating respiratory diseases.

Stewart Yeung, Keshav Raj Paudel, Gabriele De Rubis, Kylie A Williams, Philip Michael Hansbro, Kamal Dua

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stewart YeungDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW,  2007, Australia.ORCID 0009-0000-2771-9988
Keshav Raj PaudelCentre for Inflammation, Centenary Institute & University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney,  2007, Australia.ORCID 0000-0002-3591-2080
Gabriele De RubisDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW,  2007, Australia.ORCID 0000-0001-7088-396X
Kylie A WilliamsDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW,  2007, Australia.ORCID 0000-0002-5094-243X
Philip Michael HansbroCentre for Inflammation, Centenary Institute & University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney,  2007, Australia.ORCID 0000-0002-4741-3035
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW,  2007, Australia.ORCID 0000-0002-7507-1159

Funding

Maridulu Budyari Gumal- The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) funding 2022Maridulu Budyari Gumal- The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) funding 2023Triple I CAG secondment/exchange grant 2023Triple I skills advancement grant 2023University of Technology Key Technology Partnership (UTS-KTP) grant 2023
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NanoparticlesQuercetinAntioxidantsHumansRespiratory Tract DiseasesAntioxidantsQuercetinnanoformulationsnanoparticlesquercetinrespiratory diseases

Identifiers

PMID38910578
PMCPMC11216629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.